Barclays Maintains an 'Overweight' on Human Genome Sciences (HGSI); 4Q Results In Line, Benlysta Approval Next
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Human Genome Sciences (NASDAQ: HGSI), PT $40.
Barclays analyst says, "We are maintaining our rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are maintaining our rating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
